302 related articles for article (PubMed ID: 16118804)
21. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.
Murthy SB; Patnana SV; Xiao L; Rohren E; Hofstetter WL; Swisher SG; Liao Z; Lee JH; Bhutani MS; Macapinlac HA; Wang X; Ajani JA
Oncology; 2010; 78(5-6):316-22. PubMed ID: 20699623
[TBL] [Abstract][Full Text] [Related]
22. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Yamakita I; Kurokawa T; Okada M
Ann Thorac Surg; 2016 Oct; 102(4):1132-9. PubMed ID: 27319990
[TBL] [Abstract][Full Text] [Related]
23. [Esophageal cancer: outcome according to therapeutic strategy].
Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
[TBL] [Abstract][Full Text] [Related]
24. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
Onal C; Torun N; Guler OC; Yildirim BA
Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
[TBL] [Abstract][Full Text] [Related]
27. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction.
Ajani JA; Correa AM; Walsh GL; Komaki R; Lee JH; Vaporciyan AA; Rice DC; Yao JC; Maru DM; Hofstetter WL; Phan AT; Swisher SG
Cancer; 2010 Apr; 116(7):1656-63. PubMed ID: 20143431
[TBL] [Abstract][Full Text] [Related]
28. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
[TBL] [Abstract][Full Text] [Related]
29. N-staging of oesophageal and junctional carcinoma: is there still a role for EUS in patients staged N0 at PET/CT?
Foley KG; Lewis WG; Fielding P; Karran A; Chan D; Blake P; Roberts SA
Clin Radiol; 2014 Sep; 69(9):959-64. PubMed ID: 24916652
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
[TBL] [Abstract][Full Text] [Related]
31. Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer.
Muijs C; Smit J; Karrenbeld A; Beukema J; Mul V; van Dam G; Hospers G; Kluin P; Langendijk J; Plukker J
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):845-52. PubMed ID: 24411191
[TBL] [Abstract][Full Text] [Related]
32. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
Jingu K; Kaneta T; Nemoto K; Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Takai Y; Takahashi S; Yamada S
Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
[TBL] [Abstract][Full Text] [Related]
33. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer.
Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ
Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134
[TBL] [Abstract][Full Text] [Related]
34. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
36. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma.
Yen TJ; Chung CS; Wu YW; Yen RF; Cheng MF; Lee JM; Hsu CH; Chang YL; Wang HP
Dis Esophagus; 2012 Jan; 25(1):40-7. PubMed ID: 21595776
[TBL] [Abstract][Full Text] [Related]
37. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
[TBL] [Abstract][Full Text] [Related]
38. Treatment of clinical T2N0M0 esophageal cancer.
Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
[TBL] [Abstract][Full Text] [Related]
39. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
40. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]